Intellia Therapeutics, Inc. financial data

Symbol
NTLA on Nasdaq
Location
40 Erie Street, Suite 130, Cambridge, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 550 % -30.4%
Debt-to-equity 28.4 % +26.2%
Return On Equity -57.2 % -10.1%
Return On Assets -44.6 % -5.07%
Operating Margin -832 % +33.3%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 116M shares +13.7%
Common Stock, Shares, Outstanding 116M shares +13.7%
Entity Public Float 1.92B USD -46.2%
Common Stock, Value, Issued 12K USD +20%
Weighted Average Number of Shares Outstanding, Basic 110M shares +9.1%
Weighted Average Number of Shares Outstanding, Diluted 110M shares +9.1%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 57.5M USD +33.5%
Research and Development Expense 417M USD -9.02%
General and Administrative Expense 119M USD -2.62%
Costs and Expenses 536M USD -7.67%
Operating Income (Loss) -479M USD +11%
Net Income (Loss) Attributable to Parent -446M USD +14.6%
Earnings Per Share, Basic -4 USD/shares +21.7%
Earnings Per Share, Diluted -4 USD/shares +21.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 193M USD +60.5%
Marketable Securities, Current 318M USD -40.9%
Accounts Receivable, after Allowance for Credit Loss, Current 11.1M USD +24.8%
Assets, Current 582M USD -18.1%
Property, Plant and Equipment, Net 20.4M USD -29%
Operating Lease, Right-of-Use Asset 118M USD +17.5%
Assets 925M USD -21.1%
Accounts Payable, Current 13.3M USD +0.88%
Employee-related Liabilities, Current 16.8M USD -18.1%
Accrued Liabilities, Current 40.8M USD -20.2%
Contract with Customer, Liability, Current 12.2M USD -44.7%
Liabilities, Current 93.7M USD -11.3%
Contract with Customer, Liability, Noncurrent 12.5M USD -44.5%
Operating Lease, Liability, Noncurrent 70.6M USD -14.4%
Liabilities 177M USD -16.1%
Accumulated Other Comprehensive Income (Loss), Net of Tax 990K USD -70%
Retained Earnings (Accumulated Deficit) -2.49B USD -21.8%
Stockholders' Equity Attributable to Parent 748M USD -22.3%
Liabilities and Equity 925M USD -21.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -149M USD -23.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 94.3M USD +1499%
Common Stock, Shares Authorized 240M shares 0%
Common Stock, Shares, Issued 116M shares +13.7%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -54.6M USD +0.31%
Deferred Tax Assets, Valuation Allowance 783M USD +27.1%
Deferred Tax Assets, Gross 845M USD +30.2%
Operating Lease, Liability 98M USD
Payments to Acquire Property, Plant, and Equipment 735K USD -70.7%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -448M USD +13.4%
Lessee, Operating Lease, Liability, to be Paid 118M USD
Property, Plant and Equipment, Gross 77.1M USD +6.13%
Operating Lease, Liability, Current 27.4M USD +42.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 24.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 32.2M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 19.7M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 15.6M USD
Deferred Tax Assets, Operating Loss Carryforwards 297M USD +14.7%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 12.7M USD
Depreciation, Depletion and Amortization 9.97M USD -7.69%
Deferred Tax Assets, Net of Valuation Allowance 61.3M USD +89.2%
Share-based Payment Arrangement, Expense 103M USD -31.1%